26
Mon, Feb
51 New Articles

Akol Law and Esin Attorney Partnership Advise on Eczacibasi Acquisition of Gensenta from Amgen

Akol Law and Esin Attorney Partnership Advise on Eczacibasi Acquisition of Gensenta from Amgen

Turkiye
Tools
Typography
  • Smaller Small Medium Big Bigger
  • Default Helvetica Segoe Georgia Times

Akol Law has advised EIS Eczacibasi Ilac on its USD 135 million acquisition of Gensenta from the Amgen Group. Baker McKenzie Turkish affiliate Esin Attorney Partnership advised the seller.

Amgen is a US pharmaceutical company. Gensenta is the Amgen Group’s Turkish pharmaceutical affiliate.

EIS Eczacibasi Ilac is a Turkish producer of pharmaceuticals, veterinary products, hospital equipment, and cosmetics.

The Akol Law team included Founding Partner Meltem Uslu-Akol, Partner Tugce Tatari, Senior Associate Basak Belet, and Associates Dicle Yagmur Kilic, Nursu Yigit, and Kubilay Doruk Cetin.

The Esin Attorney Partnership team was led by Partners Eren Kursun and Ali Selim Demirel and included Senior Associate Guven Mavis and Associates Su Goktas, Sanem Elif Erkut, and Alp Mungan.

Editor's Note: After this article was published, Moral, Kinikoglu, Pamukkale, Kokenek announced it had advised the Eczacibasi Group on an USD 85 million loan package to finance the acquisition of a 99,96% stake in Gensenta. The firm’s team included Senior Partner Serkan Pamukkale, Partner Serra Haviyo, and Associates Orcun Turan and Deniz Yontuk.

Our Latest Issue